RxDoctor Payments Data

Timothy Kao, MD

Ophthalmology · Columbus, GANPI 1407140031

Payments from drug & device makers

$2,904in general payments, 2019–2025

Across 97 payments — averaging $29.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$741
  • Tarsus Pharmaceuticals, Inc.$536
  • Alcon$438
  • Amgen$319
  • Glaukos Corporation$135
  • Tearlab Corp$118
  • plus $618 from 13 others

What the payments were for

  • Food & beverage$2,904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,904 in reported general payments places this provider in the 55th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$384,346
Medicare patients
1,187
Services billed
3,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine73$97,690
LumiganBimatoprost156$64,604
XdemvyLotilaner20$38,586
Cyclosporine32$17,576
CombiganBrimonidine Tartrate/Timolol37$14,528
CequaCyclosporine13$10,803
Prednisolone Acetate222$7,113
RhopressaNetarsudil Mesylate14$6,982
SimbrinzaBrinzolamide/Brimonidine Tart15$5,358
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$4,566
Travoprost40$4,504
Latanoprost340$3,977
MoxifloxacinMoxifloxacin Hcl153$3,834
Dorzolamide-TimololDorzolamide/Timolol/Pf11$3,245
Brimonidine Tartrate50$3,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$741$176,821266 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$536$38,58620 claims
Sun Pharmaceutical Industries Inc.Cequa$99$10,80313 claims
Aerie Pharmaceuticals, Inc.Rhopressa$25$6,98214 claims
AlconSimbrinza$438$5,35815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →